We found that enzalutamide inhibited ER-mutant BC CRAT mRNA by qPCR (Fig. 5B) and that CRAT protein demonstrated a doublet banding pattern, as others have reported (50, 51), that was decreased in MCF7 cells by 3 days of enzalutamide treatment (Fig. 5C). Here, CRAT is linked to breast cancer.